Substantial Trade Secret Verdicts Continue with $452 Million Decision Against South Korean Company
US civil juries have returned a number of substantial trade secret verdicts against defendants over the past decade. In December 2024, a company from South Korea became the most recent defendant on the receiving end of a large trade secret jury verdict.
The lawsuit was brought by a company called Insulet. The case was filed on August 2, 2023 in the United States District Court for the District of Massachusetts and assigned case number 23-11780-FDS. The dispute involved information regarding the design, manufacturing process, and functionality of an insulin delivery system marketed by Insulet under the name Omnipod. The complaint filed by Insulet identified the product at issue as “Insulet’s first-of-its-kind ‘patch pump,’ a compact, wearable, waterproof, adhesive medical device that delivers insulin to people with insulin-dependent diabetes.” The complaint alleged that more than $600 million was invested in nearly two decades of work to bring Insulet’s product to market, whereas defendant EOFlow’s product was brought to market in South Korea in just five years, after EOFlow hired former employees of Insulet and gained access to trade secret information.
The case received media attention previously after a preliminary injunction was entered by the District Court, but the injunction was then reversed by the US Court of Appeals for the Federal Circuit in a sternly worded decision.
In December 2024, after a lengthy trial, the Massachusetts jury concluded that corporate defendants EOFlow, Inc., EOFlow Co., Ltd., and Nephria Bio, Inc., along with three individuals, misappropriated multiple trade secrets of Insulet. According to Insulet’s counsel, the jury awarded Insulet $170 million in compensatory damages and “also found that the misappropriation of three of Insulet’s trade secrets was willful and malicious and awarded an additional $282 million in exemplary or punitive damages, for a total damages award of $452 million.”
This article is available in the Jenner & Block Japan Newsletter. / この記事はJenner & Blockニュースレターに掲載されています。
Related Lawyers
Related Articles
Related Capabilities
© 2026 Jenner & Block LLP. Attorney Advertising. Jenner & Block LLP is an Illinois Limited Liability Partnership including professional corporations. This publication, presentation, or event is not intended to provide legal advice but to provide information on legal matters and/or firm news of interest to our clients and colleagues. Readers or attendees should seek specific legal advice before taking any action with respect to matters mentioned in this publication or at this event. The attorney responsible for this communication is Brent E. Kidwell, Jenner & Block LLP, 353 N. Clark Street, Chicago, IL 60654-3456. Prior results do not guarantee a similar outcome. Jenner & Block London LLP, an affiliate of Jenner & Block LLP, is a limited liability partnership established under the laws of the State of Delaware, USA and is authorised and regulated by the Solicitors Regulation Authority with SRA number 615729. Information regarding the data we collect and the rights you have over your data can be found in our Privacy Notice. For further inquiries, please contact dataprotection@jenner.com.
US civil juries have returned a number of substantial trade secret verdicts against defendants over the past decade. In December 2024, a company from South Korea became the most recent defendant on the receiving end of a large trade secret jury verdict.
The lawsuit was brought by a company called Insulet. The case was filed on August 2, 2023 in the United States District Court for the District of Massachusetts and assigned case number 23-11780-FDS. The dispute involved information regarding the design, manufacturing process, and functionality of an insulin delivery system marketed by Insulet under the name Omnipod. The complaint filed by Insulet identified the product at issue as “Insulet’s first-of-its-kind ‘patch pump,’ a compact, wearable, waterproof, adhesive medical device that delivers insulin to people with insulin-dependent diabetes.” The complaint alleged that more than $600 million was invested in nearly two decades of work to bring Insulet’s product to market, whereas defendant EOFlow’s product was brought to market in South Korea in just five years, after EOFlow hired former employees of Insulet and gained access to trade secret information.
The case received media attention previously after a preliminary injunction was entered by the District Court, but the injunction was then reversed by the US Court of Appeals for the Federal Circuit in a sternly worded decision.
In December 2024, after a lengthy trial, the Massachusetts jury concluded that corporate defendants EOFlow, Inc., EOFlow Co., Ltd., and Nephria Bio, Inc., along with three individuals, misappropriated multiple trade secrets of Insulet. According to Insulet’s counsel, the jury awarded Insulet $170 million in compensatory damages and “also found that the misappropriation of three of Insulet’s trade secrets was willful and malicious and awarded an additional $282 million in exemplary or punitive damages, for a total damages award of $452 million.”
This article is available in the Jenner & Block Japan Newsletter. / この記事はJenner & Blockニュースレターに掲載されています。
Related Lawyers
Related Articles
Related Capabilities
© 2026 Jenner & Block LLP. Attorney Advertising. Jenner & Block LLP is an Illinois Limited Liability Partnership including professional corporations. This publication, presentation, or event is not intended to provide legal advice but to provide information on legal matters and/or firm news of interest to our clients and colleagues. Readers or attendees should seek specific legal advice before taking any action with respect to matters mentioned in this publication or at this event. The attorney responsible for this communication is Brent E. Kidwell, Jenner & Block LLP, 353 N. Clark Street, Chicago, IL 60654-3456. Prior results do not guarantee a similar outcome. Jenner & Block London LLP, an affiliate of Jenner & Block LLP, is a limited liability partnership established under the laws of the State of Delaware, USA and is authorised and regulated by the Solicitors Regulation Authority with SRA number 615729. Information regarding the data we collect and the rights you have over your data can be found in our Privacy Notice. For further inquiries, please contact dataprotection@jenner.com.
News and Insights
Recognition
Jenner & Block Rises in American Lawyer Rankings for Summer Associate Experience
Jenner & Block ranked 14th nationally in The American Lawyer’s 2026 Summer Associate Satisfaction Survey, jumping 10 spots from last year. The annual survey measures summer associate satisfaction at US law firms based on ratings provided directly by summer associates across key firm qualities.
October 2, 2026
Publications
Partner Ashley Callen Discusses Potential Congressional Investigations in Reuters
Partner Ashley Callen was quoted in a Reuters article examining how Democrats could ramp up congressional investigations into Trump family business dealings if they win control of the House or Senate in the 2026 midterm elections this November.
September 30, 2026
Publications
Jenner & Block Marks Equal Time’s 25th Anniversary of Celebrating Community
Jenner & Block released the 25th edition of Equal Time, the firm’s annual inclusion and engagement report centered on “Celebrating Community.”
September 23, 2026